Diagnostic Biopsies of the Native Heart

Surgical Pathology Clinics

Volumn 5, Issue 2, 2012, Pages 401-416

  Stone, James R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amiodarone toxicity; Amyloidosis; Chloroquine toxicity; Danon disease; Endomyocardial biopsy; Fabry disease; Glycogen storage disease; Hemochromatosis; Myocarditis; Sarcoidosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE NECROTIZING EOSINOPHILIC MYOCARDITIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GIANT CELL; GIANT CELL MYOCARITIS; GLYCOGEN STORAGE DISEASE; HEART AMYLOIDOSIS; HEART FAILURE; HEART MUSCLE BIOPSY; HEART PALPITATION; HUMAN; HYPERSENSITIVITY MYOCARDITIS; IRON OVERLOAD; LYMPHOCYTIC MYOCARDITIS; LYSOSOME STORAGE DISEASE; MYOCARDITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOIDOSIS; STEM CELL TRANSPLANTATION; SUDDEN DEATH; SYNCOPE; THORAX PAIN;

EID: 84861190972     PISSN: 18759181     EISSN: 18759157     Source Type: Journal    
DOI: 10.1016/j.path.2012.04.004     Document Type: Review

References (39)

1. Leone O, Veinot JP, Angelini A, et al. Consensus statement on endomyocardial biopsy from the European Association for Cardiovascular Pathology and the Society for Cardiovascular Pathology 2011. Cardiovasc Pathol, in press.
2. Stone J.R., Basso C., Baandrup U.T., et al. Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology. Cardiovasc Pathol 2012, 21:2-16.
3. Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583-596.
4. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation 2005, 112:2047-2060.
5. Collins A.B., Smith R.N., Stone J.R. Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence. Cardiovasc Pathol 2009, 18:205-216.
6. Crotty T.B., Li C.Y., Edwards W.D., et al. Amyloidosis and endomyocardial biopsy: correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol 1995, 4:39-42.
7. Arbustini E., Morbini P., Verga L., et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 1997, 4:157-170.
8. Benson M.D., Breall J., Cummings O.W., et al. Biochemical characterization of amyloid by endomyocardial biopsy. Amyloid 2009, 16:9-14.
9. Vrana J.A., Gamez J.D., Madden B.J., et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009, 114:4957-4959.
10. Falk R.H., Dubrey S.W. Amyloid heart disease. Prog Cardiovasc Dis 2010, 52:347-361.
11. Rapezzi C., Merlini G., Quarta C.C., et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009, 120:1203-1212.
12. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
13. Dey B.R., Chung S.S., Spitzer T.R., et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 2010, 90:905-911.
14. Aretz H.T., Billingham M.E., Edwards W.D., et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987, 1:3-14.
15. Linder J., Cassling R.S., Rogler W.C., et al. Immunohistochemical characterization of lymphocytes in uninflamed ventricular myocardium: implications for myocarditis. Arch Pathol Lab Med 1985, 109:917-920.
16. Cooper L.T., Berry G.J., Rizeq M., et al. Giant cell myocarditis. J Heart Lung Transplant 1995, 14:394-401.
17. Daniels P.R., Berry G.J., Tazelaar H.D., et al. Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 2000, 9:287-291.
18. Venna N., Gonzalez R.G., Zukerberg L.R. A woman in her 90s with unilateral ptosis. N Engl J Med 2011, 365:2413-2422.
19. Fenoglio J.J., McAllister H.A., Mullick F.G. Drug related myocarditis: 1. hypersensitivity myocarditis. Hum Pathol 1981, 12:900-907.
20. Getz M.A., Subramanian R., Logemann T., et al. Acute necrotizing eosinophilic myocarditis as a manifestation of severe hypersensitivity myocarditis. Ann Intern Med 1991, 115:201-202.
21. Sabatine M.S., Poh K.K., Mega J.L., et al. A 31-year-old woman with rash, fever, and hypotension. N Engl J Med 2007, 357:2167-2178.
22. Magnani J.W., Danik H.J., Dec G.W., et al. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J 2006, 151:463-470.
23. Cooper L.T., Berry G.J., Shabetai R. Idiopathic giant-cell myocarditis - natural history and treatment. N Engl J Med 1997, 336:1860-1866.
24. Cooper L.T. Giant cell myocarditis: diagnosis and treatment. Herz 2000, 25:291-298.
25. Silverman K.J., Hutchins G.M., Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978, 58:1204-1211.
26. Uemura A., Morimoto S., Hiramitsu S., et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999, 138:299-302.
27. Ardehali H., Howard D.L., Hariri A., et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005, 150:459-463.
28. Nardi A., Brillet P.Y., Letoumelin P., et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011, 38:1368-1373.
29. Olson L.J., Edwards W.D., McCall J.T., et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987, 10:1239-1243.
30. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004, 350:2383-2397.
31. Lombardo T., Tamburino C., Bartoloni G., et al. Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study. Ann Hematol 1995, 71:135-141.
32. Ben-Ami R., Puglisi J., Haider T., et al. The Mount Sinai Hospital clinicalpathological conference: a 45-year-old man with Pompe's disease and dilated cardiomyopathy. Mt Sinai J Med 2001, 68:205-212.
33. Burwinkel B., Scott J.W., Buhrer C., et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma-2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet 2005, 76:1034-1049.
34. Balmer C., Ballhausen D., Bosshard N.U., et al. Familial X-linked cardiomyopathy (Danon disease): diagnostic confirmation by mutation analysis of the LAMP2 gene. Eur J Pediatr 2005, 164:509-514.
35. Thurberg B.L., Fallon J.T., Mitchell R., et al. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009, 119:2561-2567.
36. Staretz-Chacham O., Lang T.C., LaMarca M.E., et al. Lysosomal storage disorders in the newborn. Pediatrics 2009, 123:1191-1207.
37. Arbustini E., Grasso M., Salerno J.A., et al. Endomyocardial biopsy finding in two patients with idiopathic dilated cardiomyopathy receiving long-term treatment with amiodarone. Am J Cardiol 1991, 67:661-662.
38. Newton-Cheh C., Lin A.E., Baggish A.L., et al. A 47-year-old man with systemic lupus erythematosus and heart failure. N Engl J Med 2011, 364:1450-1460.
39. August C., Holzhausen H.J., Schmoldt A., et al. Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. J Mol Med 1995, 73:73-77.